WEBULL
News
TTRX
3.635
-15.66%
-0.675
Weekly Report: what happened at TTRX last week (1201-1205)?
Weekly Report · 9h ago
Weekly Report: what happened at TTRX last week (1124-1128)?
Weekly Report · 12/01 10:38
Director Arthur F. Golden Acquires Common Shares of Turn Therapeutics Inc
Reuters · 11/26 02:00
Director Arthur F. Golden Reports Acquisition of Turn Therapeutics Inc. Common Shares
Reuters · 11/24 16:20
Weekly Report: what happened at TTRX last week (1117-1121)?
Weekly Report · 11/24 10:45
Turn Therapeutics Inc. Officer Zuraiz Chaudhary Reports Acquisition of Common Shares
Reuters · 11/21 22:44
Interim CFO Zuraiz Chaudhary Acquires Common Shares of Turn Therapeutics Inc
Reuters · 11/18 02:24
Weekly Report: what happened at TTRX last week (1110-1114)?
Weekly Report · 11/17 10:45
Turn Therapeutics Inc. Non-GAAP EPS of -$0.07
Seeking Alpha · 11/13 15:06
*Turn Therapeutics 3Q Loss $1.9M >TTRX
Dow Jones · 11/13 13:02
*Turn Therapeutics 3Q Loss/Shr 7c >TTRX
Dow Jones · 11/13 13:02
TURN THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES
Reuters · 11/13 13:00
TURN THERAPEUTICS QTRLY EPS $-0.07
Reuters · 11/13 13:00
Press Release: Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Dow Jones · 11/13 13:00
Turn Therapeutics’ GX-03 Recognized for Dermatology Innovation
TipRanks · 11/12 12:32
Turn Therapeutics' GX-03 Named Top Innovation in Atopic Dermatitis Treatment
Reuters · 11/12 12:12
Turn Therapeutics CEO Discusses Restoring Public Trust in Science with Former CDC Director
Reuters · 11/11 21:05
Press Release: Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.
Dow Jones · 11/11 21:05
Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.
Barchart · 11/11 15:05
Weekly Report: what happened at TTRX last week (1103-1107)?
Weekly Report · 11/10 10:42
More
Webull provides a variety of real-time TTRX stock news. You can receive the latest news about Turn Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TTRX
Turn Therapeutics Inc. is a pharmaceutical and medical device development company built around a proprietary platform of technology designed to enhance drug performance. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Its products and programs include GX-03/Hexagen for Wounds (Hexagen (K160872)), GX-03/Hexagen for Derm (AtopX (K171191)), Sterile Gauze Impregnated with GX-03/Hexagen (XEAL (K183681)), Sterile Collagen/Hexagen Powder (FleX Product), GX-03/Hexagen for Moderate-Severe Eczema, and GX-03/Hexagen for Onychomycosis. GX-03/Hexagen for Wounds (Hexagen (K160872)) is a medical device for treating wounds and burns. GX-03/Hexagen for Derm (AtopX (K171191)) is a medical device for managing dermatitis.